| Possible induction of cholinesterase in epileptic patients treated with anticonvulsant drugs: relationship with lipoprotein levels. | |
| | |
MedLine Citation:
|
PMID: 15317825 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The effect of enzyme-inducing anticonvulsant drugs on the serum concentrations of lipoproteins has been widely studied. However, there is little agreement between the results with regard to the possible development of a lipoprotein profile related to an increased or decreased cardiovascular risk. It has been suggested that cholinesterase (ChE) could be induced by these drugs, something of undeniable interest as ChE appears to have a relation to the metabolism of lipoproteins. The serum activity of ChE was determined in a group of 90 adult epileptic patients (56 male and 34 female) treated with phenobarbital, phenytoin, and carbamazepine. The liver enzyme induction produced by these drugs was then evaluated by determining serum gamma-glutamyltranspherase activity and urinary excretion of D-glucaric acid. A significant increase of serum ChE (p < 0.005) was found in the group of patients compared to a control group (n = 49) with a similar distribution for age and sex. A significant correlation was found for both male and female patients between ChE and concentrations of triglycerides, phospholipids, cholesterol, low-density lipoprotein (LDL) phospholipids, LDL-cholesterol, and apolipoprotein B (p < 0.01). Similarly, in female patients, ChE had a significant correlation with the total cholesterol/high-density lipoprotein (HDL) cholesterol and LDL-cholesterol/HDL-cholesterol ratios (p < 0.01). The ChE/HDL-cholesterol relationship, which has been proposed as a marker for cardiovascular risk, presented significant correlations with the total cholesterol/HDL-cholesterol and LDL-cholesterol/HDL-cholesterol ratios in patients of both sexes (p < 0.001). In the case of epileptic patients treated with enzyme-inducing anticonvulsant drugs, there may be an association between the possible induction of ChE and the metabolism of lipoproteins containing apolipoprotein B. |
| | |
Authors:
|
María J Tutor-Crespo; Jesús Hermida; J Carlos Tutor |
Related Documents
:
|
14561435 - Serum cholesterol and impulsivity in a large sample of healthy young men. 6130595 - The effect on hdl cholesterol of oxprenolol and atenolol. 9526815 - Use of niacin, statins, and resins in patients with combined hyperlipidemia. 12837045 - Orlistat use in overweight women with mild hypercholesterolemia. 682055 - Riboflavin requirement of channel catfish fingerlings. 6439025 - Effect of soy protein and casein intake on intestinal absorption and lymphatic transpor... |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Journal of clinical pharmacology Volume: 44 ISSN: 0091-2700 ISO Abbreviation: J Clin Pharmacol Publication Date: 2004 Sep |
Date Detail:
|
Created Date: 2004-08-19 Completed Date: 2004-12-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0366372 Medline TA: J Clin Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 974-80 Citation Subset: IM |
Affiliation:
|
Laboratorio Central, Hospital Clínico Universitario, Santiago de Compostela, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Anticonvulsants / adverse effects*, blood, therapeutic use Body Weight / physiology Cholinesterases / biosynthesis*, blood Enzyme Induction / drug effects Epilepsy / drug therapy, enzymology* Female Glucaric Acid / blood, urine Humans Lipoproteins / blood* Male Middle Aged gamma-Glutamyltransferase / blood |
| Chemical | |
Reg. No./Substance:
|
0/Anticonvulsants; 0/Lipoproteins; 25525-21-7/Glucaric Acid; EC 2.3.2.2/gamma-Glutamyltransferase; EC 3.1.1.8/Cholinesterases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 pheno...
Next Document: Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/...